EpiCept Corporation

EpiCept Corporation

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Contact Details

Office Address

EpiCept Corporation
777 Old Saw Mill River Road
Tarrytown, NY, USA 10591
Phone: (914) 606-3500
Fax: (914) 606-3501

Executives

Chairman

Robert G. Savage

President, CEO, and Director

John V. Talley

Business Reviews for EpiCept Corporation

Related Companies